Core Viewpoint - The company experienced significant stock price volatility, with a cumulative deviation of 45.65% over two consecutive trading days, indicating abnormal fluctuations in its stock performance [1] Financial Performance - The company's net profit for 2024 was -19.8849 million, representing a decline of 108.18% compared to 2023 [1] - In the first quarter of 2025, the net profit was -3.5647 million, a decrease of 272.34% year-on-year [1] Shareholder Activity - During the period of stock price volatility, the major shareholder, Yiwos Trading Co., Ltd., reduced its holdings through centralized bidding and block trading, accounting for 0.23% of the total share capital [1] Disclosure and Compliance - The company confirmed that there were no corrections or supplements needed for previously disclosed information, and no undisclosed significant information was found that could impact stock trading prices [1] - The controlling shareholder and actual controller have no undisclosed major matters [1]
拓新药业:公司股票在2025年5月15日和16日连续两个交易日累计偏离45.65%